Allarity Therapeutics to Present at Biomarkers Europe 2023
02 Ottobre 2023 - 1:00PM
- Allarity
will present on development of several drug-specific DRP® companion
diagnostics, and participate in a panel discussion with speakers
from Merck and Roche
BOSTON, October 2, 2023 —
Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq:
ALLR), a clinical-stage pharmaceutical company developing novel
oncology therapeutics together with drug-specific DRP® companion
diagnostics for personalized cancer care, is pleased to announce
that the Company has been invited to give a presentation at
Biomarkers Europe 2023. The presentation will focus on Allarity’s
development of drug-specific DRP® companion diagnostics (CDx) for
oncology therapeutics, featuring clinical validation for several
exemplary DRP® CDx.
Presentation details include:
Event: Biomarkers Europe 2023Presentation title: A Gene
Expression Based Biomarker for Predicting Response to Treatment
with Dovitinib and with IxabepiloneDate: November 14-15,
2023Location: Berlin, GermanyWeb:
https://www.oxfordglobal.co.uk/biomarkers-europe/
In addition to its presentation, Allarity is honored to
participate in a panel discussion titled "Prediction Of Drug
Response Using An Ex Vivo Organ Culture (EVOC) On Oncology
Patients, Clinical Trial Development And Patient Testing" at the
same conference. This panel discussion will be moderated by
Jonathan Krell, Clinical Senior Lecturer at Imperial College
London, and will feature esteemed panelists:
- Anna Maria Lara Coenen-Stass, Associate Director, Merck
KGaA
- Thomas Jensen, Co-Founder, Allarity Therapeutics
- Priscila Teixeira, Head of Biomarker, Bioanalytic and Biosample
Office, Roche
The Company will also attend the upcoming ThinkEquity Conference
in October in New
York:https://www.think-equity.com/thinkequity-conference
Allarity representatives will be available for one-on-one
meetings to discuss business development opportunities. The Company
invites attendees to schedule one-on-one meetings in advance.
About Allarity
Therapeutics Allarity Therapeutics,
Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of
cancer guided by its proprietary and highly validated companion
diagnostic technology, the DRP® platform. The Company has a
mature portfolio of three drug candidates: stenoparib, a PARP
inhibitor in Phase 2 development for ovarian cancer, and in Phase 1
development for advanced solid tumors in a combination treatment
with dovitinib, a pan-tyrosine kinase inhibitor (pan-TKI) that has
previously been developed through Phase 3 in renal cancer; and
IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in
the U.S. and marketed by R-PHARM U.S. for the treatment of
second-line metastatic breast cancer, currently in Phase 2
development in Europe for the same indication. Additionally, the
Company has rights in two secondary assets: 2X-111, a liposomal
formulation of doxorubicin for metastatic breast cancer and/or
glioblastoma multiforme (GBM), which is the subject of discussions
for a restructured out-license to Smerud Medical Research
International AS; and LiPlaCis®, a liposomal formulation of
cisplatin and its accompanying DRP®, being developed via a
partnership with CHOSA Oncology AB for late-stage metastatic breast
cancer. The Company is headquartered in the United States and
maintains an R&D facility in Hoersholm, Denmark. For more
information, please visit the Company’s website
at www.Allarity.com.
About the Drug Response Predictor –
DRP® Companion
Diagnostic Allarity uses its
drug-specific DRP® to select those patients who, by the genetic
signature of their cancer, are found to have a high likelihood of
responding to the specific drug. By screening patients before
treatment, and only treating those patients with a sufficiently
high DRP® score, the therapeutic response rate can be significantly
increased. The DRP® method builds on the comparison of sensitive
vs. resistant human cancer cell lines, including transcriptomic
information from cell lines combined with clinical tumor biology
filters and prior clinical trial outcomes. DRP® is based on
messenger RNA from patient biopsies. The DRP® platform has proven
its ability to provide a statistically significant prediction of
the clinical outcome from drug treatment in cancer patients in 37
out of 47 clinical studies that were examined (both retrospective
and prospective), including ongoing, prospective Phase 2 trials of
Stenoparib and IXEMPRA®. The DRP® platform, which can be used in
all cancer types and is patented for more than 70 anti-cancer
drugs, has been extensively published in peer-reviewed
literature.
Follow Allarity
on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx
Forward-Looking
Statements This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements provide Allarity’s current expectations or forecasts of
future events. The words “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,”
“towards,” “would” and similar expressions may identify
forward-looking statements, but the absence of these words does not
mean that a statement is not forward-looking. These forward-looking
statements include, but are not limited to, statements related to
the expected availability of capital to fund its anticipated
clinical trials, statements related to advancing dovitinib in
combination with stenoparib or another therapeutic candidate or
other approved drug, any statements related to ongoing clinical
trials for stenoparib as a monotherapy or in combination with
another therapeutic candidate for the treatment of advanced ovarian
cancer, or ongoing clinical trials (in Europe) for
IXEMPRA® for the treatment of metastatic breast cancer,
statements relating to the effectiveness of the Company’s
DRP® companion diagnostics platform in predicting whether a
particular patient is likely to respond to a specific drug, and
statements related to the Company’s ability to maintain compliance
with the Nasdaq Listing Rule. Any forward-looking statements in
this press release are based on management’s current expectations
of future events and are subject to multiple risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that the Company is not able to
raise sufficient capital to support its current and anticipated
clinical trials, the risk that results of a clinical study do
not necessarily predict final results and that one or more of the
clinical outcomes may materially change following more
comprehensive reviews of the data, and as more patient data become
available, the risk that results of a clinical study are subject to
interpretation and additional analyses may be needed and/or may
contradict such results, the receipt of regulatory approval for
dovitinib or any of our other therapeutic candidates or, if
approved, the successful commercialization of such products, the
risk of cessation or delay of any of the ongoing or planned
clinical trials and/or our development of our product candidates,
the risk that the results of previously conducted studies will not
be repeated or observed in ongoing or future studies involving our
therapeutic candidates, and the risk that the current COVID-19
pandemic will impact the Company’s current and future clinical
trials and the timing of the Company’s preclinical studies and
other operations. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our Form 10-K annual report on file with
the Securities and Exchange Commission, available at the
Securities and Exchange Commission’s website
at www.sec.gov , and as well as discussions of
potential risks, uncertainties and other important factors in the
Company’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and the Company undertakes no duty to update this
information unless required by law.
###
Company Contact:
investorrelations@allarity.com
U.S. Media
Contact: Mike
Beyer Sam Brown,
Inc. +1 (312)
961-2502
mikebeyer@sambrown.com EU
Media
Contact: Thomas
Pedersen Carrotize
PR &
Communications +45
6062
9390 tsp@carrotize.com
- Allarity Therapeutics - Conference Participation
Grafico Azioni Allarity Therapeutics (NASDAQ:ALLR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Allarity Therapeutics (NASDAQ:ALLR)
Storico
Da Giu 2023 a Giu 2024